Barclays initiates Repligen at Overweight with $150 price target, optimistic about bioprocessing industry

From Barchart: 2025-06-24 16:36:00

Barclays has given Repligen Corporation (NASDAQ:RGEN) an Overweight rating and a $150 price target, praising its strong position in the bioprocessing industry and exposure to early-stage clinical workflows. The company’s focus on clinical-stage manufacturing allows its products to be integrated early in drug development, growing with therapies. Concerns about weakening demand for cell and gene therapies persist, but Barclays remains optimistic about the industry’s growth. Despite a recent drop in Repligen shares, Barclays sees this as a buying opportunity, highlighting the company’s resilience and strategic importance in biotech manufacturing.



Read more at Barchart:: Barclays Initiates Repligen at Overweight, Sees Se…